- Home
- IDAI vs TOVX Comparison
IDAI vs TOVX Comparison
Compare IDAI & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IDAI | TOVX |
|---|---|---|
| Founded | 2016 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 10.4M |
| IPO Year | 2022 | 2012 |
Fundamental Metrics
Financial Performance| Metric | IDAI | TOVX |
|---|---|---|
| Price | $2.45 | $0.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $1.00 |
| AVG Volume (30 Days) | 32.1K | ★ 24.2M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 76.50 | ★ 89.07 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $103.06 | N/A |
| Revenue Next Year | $140.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.80 | $0.16 |
| 52 Week High | $5.28 | $1.47 |
Technical Indicators
Market Signals| Indicator | IDAI | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 65.09 |
| Support Level | $2.31 | $0.18 |
| Resistance Level | $2.80 | $0.53 |
| Average True Range (ATR) | 0.17 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 24.39 | 57.00 |
Price Performance
Historical ComparisonAbout IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.